# EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot

> **NCT03791593** · PHASE2 · COMPLETED · sponsor: **Fundació Institut Germans Trias i Pujol** · enrollment: 46 (actual)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** Evolocumab

## Key facts

- **NCT ID:** NCT03791593
- **Lead sponsor:** Fundació Institut Germans Trias i Pujol
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-03
- **Primary completion:** 2021-06-30
- **Final completion:** 2022-07-20
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03791593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03791593, "EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03791593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*